GENSIGHT BIOLOGICS SA revenue for the last year amounted to 3.31 M USD, the most of which — 1.40 M USD — came from its highest performing source at the moment, Novel Therapies for Mitochondrial and Neurodegenerative Disease, the year earlier bringing 2.76 M USD. The greatest contribution to the revenue figure was made by France — last year it brought GENSIGHT BIOLOGICS SA 1.40 M USD, and the year before that — 2.76 M USD.